IGF-1 LR3 · Research brief

Powerlifters IGF-1 LR3 Protocol — Dosing and Timing

Real Peptides Research TeamEditorial

Updated June 30, 20268 min read

58 WORDS

Short answer

Key takeaways

IGF-1 LR3 has a half-life of 20–30 hours, allowing once-daily dosing but requiring dose periodization to prevent receptor desensitization from cumulative exposure.
The powerlifters IGF-1 LR3 protocol uses 60–80mcg on max-effort days, 30–40mcg on dynamic-effort days, and zero on rest days to match anabolic signaling with training intensity.
Cycle length should not exceed 4–6 weeks, followed by equal or longer off-time to allow IGF-1 receptor density in muscle tissue to normalize before the next cycle.
Injection site selection should target the primary muscle groups recruited during that session. Triceps and pectoralis on bench days, glutes and quads on squat days.
IGF-1 LR3 administered without sufficient dietary protein (1.8–2.2g/kg bodyweight daily) and caloric surplus produces negligible strength adaptation regardless of dose.
Most powerlifters see diminishing returns after week four of continuous use because IGF-1 receptors downregulate in response to sustained exposure. Pulsed dosing preserves sensitivity longer than daily fixed doses.

Powerlifters who run IGF-1 LR3 without understanding receptor dynamics typically see initial strength jumps in week one or two, then nothing. The compound stops working not because the peptide degrades. IGF-1 Long R3 has a half-life of 20–30 hours, far longer than endogenous IGF-1's 12-minute circulation time. But because continuous exposure downregulates IGF-1 receptors in skeletal muscle tissue. The muscle stops responding. The protocol that works for powerlifters isn't the one bodybuilders use for hypertrophy. It's built around peak receptor sensitivity during max-effort training days, localized injection into worked muscle groups, and strict cycle length limits to preserve long-term responsiveness.

We've worked with strength athletes across multiple federations who integrate research peptides into periodized training blocks. The gap between protocols that deliver measurable strength gains and those that waste money comes down to three factors most online forums ignore entirely: injection timing relative to training stimulus, site rotation strategy, and cycle-to-cruise ratio.

What is the powerlifters IGF-1 LR3 protocol?

The powerlifters IGF-1 LR3 protocol typically involves 20–80mcg daily dosing, administered post-workout into trained muscle groups, run in 4–6 week cycles with equal off-time to prevent receptor desensitization. IGF-1 LR3 binds to IGF-1 receptors with lower affinity than native IGF-1 but remains active significantly longer. Creating sustained anabolic signaling in muscle tissue without the rapid clearance that limits endogenous IGF-1. Powerlifters use this extended activity window to amplify recovery and protein synthesis after high-intensity training sessions, particularly during strength-focused mesocycles where tissue repair capacity becomes the limiting factor in progressive overload.

The compound doesn't replace progressive overload or dietary protein. It amplifies the anabolic response to training stimulus that's already present. IGF-1 LR3 administered without sufficient mechanical tension, caloric surplus, or leucine-rich protein intake produces negligible strength adaptation. The receptor activation matters only if the muscle has a reason to grow.

This article covers the specific dosing ranges used in strength training contexts, injection timing and site selection strategies, cycle length and receptor management protocols, and the mistakes that cause most powerlifters to see no measurable benefit from IGF-1 LR3 despite spending significant money on the compound.

Why Powerlifters Use IGF-1 LR3 Differently Than Bodybuilders

Bodybuilders chase hypertrophy. Total muscle volume increase across all muscle groups over 12–16 week cycles. Powerlifters care about one metric: how much weight moves in competition lifts. That difference reshapes the entire powerlifters IGF-1 LR3 protocol. A bodybuilder might run 40–60mcg daily for eight weeks straight, rotating injection sites across every major muscle group to achieve balanced growth. A powerlifter running the same protocol would see strength plateau by week four because continuous IGF-1 receptor stimulation causes downregulation. The muscle becomes less responsive to the compound over time, not more.

The powerlifting-specific approach uses higher peak doses (60–80mcg) on max-effort and dynamic-effort training days, administered immediately post-workout into the primary muscle groups recruited during that session. On rest days or accessory work days, the dose drops to 20–30mcg or zero. This pulsed exposure pattern maintains receptor sensitivity while concentrating anabolic signaling during the 48–72 hour window when muscle protein synthesis rates are elevated post-training. Research on IGF-1 receptor biology shows that intermittent high-intensity stimulation produces greater downstream mTOR activation than constant low-grade stimulation. The same principle that makes cluster sets more effective than straight sets for maximal strength development.

Localized injection matters more for powerlifters than bodybuilders because competition lifts recruit specific muscle groups in coordinated patterns. A bodybuilder might inject IGF-1 LR3 into the vastus lateralis one day, the posterior deltoid the next, rotating sites to distribute hypertrophic stimulus. A powerlifter preparing for a meet injects into the triceps, anterior deltoid, and pectoralis major on bench press days. The exact muscles that limit lockout strength. On squat days, the injection goes into the vastus medialis and glutes. The muscles that drive hip extension out of the hole. Site-specific injection doesn't keep the peptide localized to that muscle. IGF-1 LR3 circulates systemically within hours. But it does create a brief concentration gradient that amplifies receptor activation in recently trained tissue.

The Dose-Timing Framework for Strength Training

Most powerlifters dose IGF-1 LR3 once daily at a fixed amount. 40mcg every morning, for example. That approach ignores the compound's pharmacokinetics entirely. IGF-1 Long R3 has a half-life of approximately 20–30 hours, meaning a single 60mcg dose on Monday morning still produces detectable serum levels on Tuesday evening. Dosing again on Tuesday creates cumulative exposure that exceeds the threshold for receptor downregulation by mid-week. The result: diminished response exactly when training intensity peaks during the week's heaviest sessions.

The solution is dose periodization tied to training intensity. On max-effort days. When the athlete is working up to a daily 1-rep max or heavy triple in a competition lift. Administer 60–80mcg immediately post-workout, injected into the primary movers for that lift. On dynamic-effort days. Speed work with submaximal loads. Dose at 30–40mcg post-session. On accessory-only days or active recovery days, skip the dose entirely or use 20mcg if the training block is particularly demanding. This creates a weekly dose profile that matches the actual anabolic demand placed on the muscle tissue: high IGF-1 exposure when mechanical tension is highest, minimal exposure when the training stimulus is low.

Timing relative to meals matters less than timing relative to training. IGF-1 LR3 doesn't require fasted administration. Insulin and IGF-1 pathways are distinct, and postprandial insulin elevation doesn't meaningfully interfere with IGF-1 receptor binding. What does matter is the presence of circulating amino acids during the IGF-1 activity window. Administering the peptide post-workout, followed within 30–60 minutes by a leucine-rich protein meal (35–50g protein with at least 3g leucine), synchronizes IGF-1 receptor activation with amino acid availability. The two conditions required for muscle protein synthesis to exceed baseline rates. IGF-1 without protein is wasted; protein without IGF-1 signaling underperforms what's possible with both present.

Cycle Length and Receptor Preservation

The single most common mistake powerlifters make with IGF-1 LR3 is running cycles too long. Eight-week cycles are standard in bodybuilding forums. And they're too long for maintaining receptor sensitivity in strength athletes. By week six of continuous or near-continuous IGF-1 LR3 exposure, even with periodized dosing, IGF-1 receptor density in skeletal muscle begins declining. The muscle adapts to the elevated signaling by reducing receptor expression. A protective mechanism that prevents overstimulation. Once receptor density drops, increasing the dose doesn't restore the response. The athlete is injecting more peptide into tissue that can't utilize it.

The powerlifters IGF-1 LR3 protocol that preserves long-term responsiveness uses 4–6 week cycles maximum, followed by equal or longer off-time before the next cycle. A 5-week cycle requires 5–6 weeks completely off IGF-1 LR3 before starting again. During the off-cycle, endogenous IGF-1 production continues, receptor density normalizes, and the muscle regains full sensitivity to exogenous IGF-1 when the next cycle begins. Athletes who run back-to-back cycles with only 2–3 weeks between see diminishing returns on every subsequent cycle. Each one delivers less strength gain than the previous, and by the third or fourth cycle, the compound produces no measurable effect at any dose.

Cycle timing within a periodized training year matters. The ideal window for an IGF-1 LR3 cycle is during a strength-focused mesocycle when training intensity is high but volume is moderate. Typically the 4–6 weeks leading into a peaking phase before competition. Running IGF-1 LR3 during a high-volume hypertrophy block wastes the compound's strength-specific benefits; running it during a deload or taper phase provides no training stimulus to amplify. The peptide works best when mechanical tension is maximal and recovery demand is highest. Exactly the conditions present during a properly structured strength block.

Powerlifters IGF-1 LR3 Protocol: Dosing Comparison

Training Day Type	Dose Range	Injection Timing	Target Muscle Groups	Rationale
Max-effort (1–3RM)	60–80mcg	Immediately post-workout	Primary movers for that lift (e.g., triceps/pecs/delts on bench day)	Maximizes IGF-1 receptor activation during peak protein synthesis window following high mechanical tension
Dynamic-effort (speed work)	30–40mcg	Immediately post-workout	Same muscle groups trained that session	Maintains anabolic signaling without cumulative receptor saturation
Accessory/volume day	20–30mcg or skip	Post-workout if dosed	Secondary/accessory muscles trained	Minimal dose preserves receptor sensitivity; skipping entirely is equally valid
Rest/recovery day	0mcg (skip dose)	N/A	N/A	Allows IGF-1 receptor density to normalize between high-intensity sessions
Professional Assessment	Higher peak doses with intermittent exposure produce better strength outcomes than moderate daily doses. Receptor downregulation is the limiting factor, not total weekly dose	Apply this framework during strength-focused mesocycles (4–6 weeks), not year-round	Rotate injection sites within the same muscle group session-to-session to avoid scar tissue buildup	IGF-1 LR3 amplifies recovery capacity during high-intensity blocks; it does not replace progressive overload or adequate protein intake

What If: Powerlifters IGF-1 LR3 Protocol Scenarios

What If I Miss a Scheduled Dose on a Max-Effort Day?

Skip it entirely. Do not double-dose the next day. IGF-1 LR3's 20–30 hour half-life means a missed dose on Monday still leaves residual peptide activity on Tuesday. Doubling up creates a concentration spike that accelerates receptor downregulation without proportional strength benefit. The training stimulus from Monday's session already occurred; adding IGF-1 on Tuesday won't retroactively amplify protein synthesis that peaked 24–48 hours earlier. Resume normal dosing on the next scheduled training day.

What If I Feel No Strength Increase After Two Weeks?

Review injection timing and site selection first. Most

All compounds discussed on this page are sold for research use only and are not for human consumption.

References

Peer-reviewed sources on IGF-1 LR3 indexed in PubMed, listed for research context. Real Peptides supplies IGF-1 LR3 for laboratory research use only.

IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep. American journal of physiology. Endocrinology and metabolism, 2025. PMID 39679943. doi:10.1152/ajpendo.00259.2024
Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice. Journal of Alzheimer's disease : JAD, 2025. PMID 39610283. doi:10.1177/13872877241299056
Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris. Applied microbiology and biotechnology, 2023. PMID 37261455. doi:10.1007/s00253-023-12606-0
Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets. Journal of developmental origins of health and disease, 2023. PMID 37114757. doi:10.1017/S2040174423000090
Long R3 insulin-like growth factor-I (IGF-I) infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig. The Journal of endocrinology, 1995. PMID 7561636. doi:10.1677/joe.0.1460247

Questions

IGF-1 Long R3 is a synthetic analog of human IGF-1 with an arginine substitution at position 3, extending its half-life to 20–30 hours compared to endogenous IGF-1's 12-minute circulation time. This extended activity window allows once-daily dosing and sustained IGF-1 receptor activation in muscle tissue following training, whereas native IGF-1 is cleared too rapidly to produce meaningful anabolic effects when administered exogenously. The tradeoff is lower receptor binding affinity — IGF-1 LR3 binds less tightly than native IGF-1, requiring higher doses to achieve comparable receptor occupancy. For powerlifters, the extended half-life is the critical advantage because it allows strategic dosing around high-intensity training sessions without requiring multiple daily injections.

No — continuous low-dose IGF-1 LR3 administration causes IGF-1 receptor downregulation in skeletal muscle, rendering the compound progressively less effective regardless of dose. Even at 20–30mcg daily, sustained exposure over 8–12 weeks reduces receptor density as the muscle adapts to chronic signaling. The result is that by month three, the athlete is spending money on a peptide that produces no measurable strength or recovery benefit. Effective use requires cycling: 4–6 weeks on, followed by equal or longer off-time to allow receptor expression to normalize. Athletes attempting year-round protocols consistently report diminishing returns starting around week six, with near-total loss of response by week ten.

For squat-dominant training sessions, inject IGF-1 LR3 into the vastus medialis (inner thigh) or gluteus medius (upper outer quadrant of the glute) immediately post-workout. These are the primary hip and knee extensors recruited during the squat, and localized injection creates a brief concentration gradient that amplifies IGF-1 receptor activation in recently trained tissue. While the peptide circulates systemically within hours, the initial site-specific delivery enhances uptake in muscles with elevated blood flow and metabolic activity from training. Rotate between left and right limbs session-to-session to prevent scar tissue buildup at a single injection site.

IGF-1 LR3 can lower blood glucose by enhancing insulin-independent glucose uptake into muscle and fat cells, but clinically significant hypoglycemia is rare at doses used in strength training protocols (20–80mcg daily). The risk increases in athletes combining IGF-1 LR3 with exogenous insulin or running aggressive caloric deficits without adequate carbohydrate intake around training. Symptoms include shakiness, confusion, cold sweats, and sudden energy crashes 2–4 hours post-injection. Mitigation: consume 30–50g carbohydrates within one hour of IGF-1 LR3 administration, prioritize post-workout meals, and avoid dosing during fasted training sessions or extended fasting periods.

Most powerlifters report measurable strength increases — defined as 5–10 pound improvements in competition lift maxes — within 10–14 days of starting a properly structured IGF-1 LR3 cycle, assuming training intensity and protein intake are adequate. The initial response reflects enhanced recovery capacity and accelerated protein synthesis in trained muscle groups, not structural hypertrophy. Gains plateau or reverse after week 4–6 as IGF-1 receptors downregulate, which is why cycle length must be limited. Athletes who see no strength change by week two should verify peptide quality, injection timing relative to training, and dietary protein intake before assuming non-response.

Yes — IGF-1 LR3 is commonly stacked with growth hormone secretagogues like GHRP-2 or ibutamoren (MK-677) to amplify endogenous GH release, which increases hepatic IGF-1 production and creates additive anabolic signaling. The [GHRP-2](https://www.realpeptides.co/products/ghrp-2/?utm_source=other&utm_medium=seo&utm_campaign=mark_ghrp_2) or [MK-677](https://www.realpeptides.co/products/mk-677/?utm_source=other&utm_medium=seo&utm_campaign=mark_mk_677) doses are typically administered before bed to coincide with natural GH pulses, while IGF-1 LR3 is dosed post-training. This separation prevents receptor competition and optimizes each compound's anabolic window. Avoid stacking IGF-1 LR3 with insulin unless under medical supervision — the combined glucose-lowering effects significantly increase hypoglycemia risk.

Extending the cycle beyond six weeks accelerates IGF-1 receptor downregulation without proportional strength benefit — by week seven or eight, receptor density has declined to the point where even doubled doses produce minimal anabolic response. The muscle has adapted to chronic IGF-1 signaling by reducing receptor expression, a protective mechanism against overstimulation. Additionally, prolonged cycles require longer recovery periods before the next cycle can begin: an eight-week cycle may require 10–12 weeks off to fully restore receptor sensitivity, compared to 5–6 weeks off after a four-week cycle. Athletes chasing 'more gains' by extending cycles end up with less responsiveness long-term.

Yes — IGF-1 LR3 is a prohibited substance under WADA guidelines and is detectable via immunoassay testing that measures elevated IGF-1 levels in serum. While the peptide itself has a 20–30 hour half-life, elevated IGF-1 concentrations can persist for 5–7 days post-administration. Some federations use more sophisticated LC-MS/MS testing that can differentiate between endogenous IGF-1 and synthetic analogs like Long R3 based on structural markers. Athletes competing in tested federations should discontinue IGF-1 LR3 at least 14–21 days before competition and verify their federation's specific testing protocols and detection windows.

Yes — IGF-1 receptor density and signaling pathways in skeletal muscle are not meaningfully different between sexes, so the same dose-timing framework applies. However, women typically use the lower end of the dose range (20–60mcg on max-effort days, 15–30mcg on dynamic-effort days) because absolute muscle mass and training volume are generally lower. Cycle length and off-time recommendations remain identical: 4–6 weeks on, equal or longer off. Women should monitor for androgenic side effects if stacking IGF-1 LR3 with other compounds, but IGF-1 itself does not possess androgenic activity.

No — IGF-1 LR3 does not suppress endogenous hormone production the way anabolic steroids suppress testosterone, so traditional post-cycle therapy with SERMs or aromatase inhibitors is unnecessary. The primary concern post-cycle is receptor resensitization: IGF-1 receptors in muscle tissue need time off exogenous IGF-1 to upregulate receptor expression back to baseline. This occurs naturally during the off-cycle period (4–6 weeks minimum). Some athletes report temporary reductions in training capacity during the first 1–2 weeks off-cycle as anabolic signaling returns to baseline — this is expected and resolves without intervention.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA